JD.com's domestic mobile phone sales have increased by 200% month-on-month, and mobile phone supply chain manufacturers are expected to release performance elasticity.

According to media reports, as of January 20th at 12:00, the national subsidy activities in Peking, Hubei, Jiangsu, Zhejiang, and Shaanxi are fully launched on JD.com, and activities in other provinces and cities are also being rolled out. Among the provinces and cities where the national subsidy is launched, smartphone sales have increased by 200% month-on-month, and tablet sales have increased by 300%.

cls.cn18:58 ET

With the highest net profit projected to increase by more than double, Weigao Orthopedics is expected to "recover" in 2024, as orthopedic consumables enter a stable period for centralized procurement.

① Regarding the reasons for the performance changes, Weigao Orthopedics attributes it to the company's implementation of volume-based procurement policies and the proactive adjustment of relevant Business strategies, as well as the contribution of new product lines and overseas markets; ② Another orthopedic company, Double Medical Technology Inc., also saw significant recovery in performance. Weigao Orthopedics General Manager Lu Junqiang mentioned that although there was a substantial price drop before and after the centralized procurement, the main product lines achieved sustained growth in sales volume, surgical volume, and market share.

cls.cnJan 21 10:13 ET

Boe Technology Group is expected to turn a profit in non-recurring net profit for the first time in three years. Can the panel industry maintain its growth trend in 2025? | Interpretations

① Boe Technology Group released its performance forecast for 2024, expecting a positive Net income for the first time in three years; ② The company stated that demand-based production of LCDs, policy incentives, and the continuous growth of OLED shipments are the main reasons for the company's performance growth; ③ Analysts believe that in 2025, LCD production will primarily focus on "controlling production and stabilizing prices," while OLED will continue to penetrate the market.

cls.cnJan 20 10:44 ET

Huadong Medicine has obtained approvals for three new products at the start of the year, which is nearly half of last year's total.|Quick read announcement.

1. Huadong Medicine announced today that three products have received approval for market entry, while a total of seven products were approved last year; 2. Among them, a hyaluronic acid product for medical aesthetics and a chemical drug for the treatment of ovarian cancer received domestic approval, while a medical instrument for assessing kidney function received approval in the USA; 3. Huadong Medicine believes that the approvals will not have a significant impact on the company's current financial situation and operational results.

cls.cnJan 20 10:31 ET

Opening more new stores but struggling to make a profit, Yixintang Pharmaceutical's net income is expected to drop by over 70% last year | Interpretations

① Yixintang Pharmaceutical expects a Net income decline of 72.7%–81.8% in 2024 compared to the same period last year; ② The company stated that the performance variation is mainly due to the expansion of the company's stores leading to increased Operation costs, as well as some new and relatively new stores being in the initial loss stage.

cls.cnJan 17 09:47 ET

AI drives the growth in demand for optical devices, with Tengjing Technology expected to increase its net profit by up to 80% in 2024.

① Tengjing Technology expects a year-on-year growth of 51.24%-80.05% in Net income for the fiscal year 2024, and a year-on-year growth of 64.75%-97.7% in net income after deductibles; ② In recent years, the company's applications in the field of precision optical components have gradually increased. In addition to the optical communication field, there are also applications in Medical, Semiconductors equipment, AR glasses, and quantum information.

cls.cnJan 16 08:06 ET